How does ezetimibe work, and will adding it to a patient on losartan, metoprolol, rosuvastatin, and semaglutide with a coronary artery calcium score of 1100 cause a significant increase in the CAC score?

Mechanism of Action and Impact on Coronary Artery Calcium Score

How Ezetimibe Works

Ezetimibe blocks the intestinal absorption of dietary and biliary cholesterol by inhibiting cholesterol translocation from the gastrointestinal lumen into jejunal enterocytes, reducing LDL-C by approximately 18-25% when added to statin therapy. 1, 2, 3

• Ezetimibe undergoes enterohepatic recirculation with minimal systemic exposure and does not adversely affect statin pharmacokinetics 3
• When combined with statins, it provides an additional 20-25% LDL-C reduction beyond statin monotherapy 1
• The drug works synergistically with statins: statins block cholesterol synthesis in the liver while ezetimibe blocks absorption in the intestine 4

Effect on Coronary Artery Calcium Score

Adding ezetimibe to your current regimen will NOT cause a significant increase in your CAC score; in fact, evidence demonstrates that ezetimibe actually reduces plaque burden and may modestly decrease CAC progression. 5, 6

Evidence for Plaque Regression

• In a study of 231 patients, total plaque area decreased by -3.05 mm² after addition of ezetimibe, compared to an increase of +6.89 mm² in the 2 years before ezetimibe was added (P<0.01) 6
• The combination of ezetimibe plus rosuvastatin significantly reduced plaque burden, plaque cross-sectional area, and percentage of necrotic plaque composition at 12 months compared to rosuvastatin alone (P<0.05) 5
• These plaque-stabilizing effects appear related to potent anti-inflammatory effects beyond simple LDL-C lowering 5

Clinical Context for Your CAC Score of 1100

With a CAC score of 1100, you are at very high cardiovascular risk—equivalent to secondary prevention populations—and adding ezetimibe to your rosuvastatin is strongly indicated to achieve aggressive LDL-C targets. 7

• CAC ≥1000 denotes risk equivalent to established atherosclerotic cardiovascular disease 7
• Your target LDL-C should be <55 mg/dL with ≥50% reduction from baseline 1, 8
• If rosuvastatin alone does not achieve this goal, adding ezetimibe 10 mg daily is a Class I, Level A recommendation 1, 8

Recommendation for Your Specific Case

Add ezetimibe 10 mg once daily to your current rosuvastatin regimen; this combination is safe with your other medications (losartan, metoprolol, semaglutide) and will reduce cardiovascular events without worsening your CAC score. 1, 9

Safety Profile with Your Current Medications

• A randomized trial specifically evaluated the combination of amlodipine/losartan/rosuvastatin/ezetimibe and found no adverse drug reactions in the quadruple combination group 9
• Ezetimibe does not interact with losartan, metoprolol, or semaglutide 2
• The combination of statin plus ezetimibe has an excellent safety record with minimal additional risk beyond statin monotherapy 4, 10

Monitoring Plan

• Recheck lipid panel 8 weeks (±4 weeks) after starting ezetimibe to assess LDL-C response 8
• Obtain baseline ALT and CK before intensifying therapy 8
• If LDL-C remains ≥70 mg/dL after 8-12 weeks on rosuvastatin plus ezetimibe, escalate to a PCSK9 inhibitor 8, 11

Expected Outcomes

• Expect an additional 20-25% reduction in LDL-C beyond your current rosuvastatin dose 1, 4
• The IMPROVE-IT trial demonstrated a 6.4% relative risk reduction in major cardiovascular events when ezetimibe was added to statin therapy 1
• Plaque stabilization and modest regression can occur, not progression 5, 6

Common Pitfalls to Avoid

• Do not delay adding ezetimibe while waiting to see if lifestyle changes alone will suffice; with CAC of 1100, aggressive pharmacologic therapy is immediately warranted 7
• Do not increase rosuvastatin dose (e.g., from 20 mg to 40 mg) instead of adding ezetimibe; doubling statin dose yields only ~6% additional LDL-C lowering but markedly increases myopathy risk 8
• Do not add fibrates or niacin for additional lipid lowering; they lack cardiovascular outcome benefit when added to statin therapy 8
• Do not stop smoking cessation efforts; this remains the single most effective intervention for overall cardiovascular risk reduction in your situation 8